ArticleBlood cancer journal2025
Comparing the efficacy and safety of venetoclax combined with hypomethylating agents versus intensive chemotherapy as induction therapy in newly diagnosed core binding factor acute myeloid leukemia patients.
Jingyi Shen, Meng Shan, Mengqian Chu, Yiming Cai, Jingwen Rui, Suning Chen, Depei Wu, Yang Xu
Abstract readLetter
In one paragraphArticle in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Jingyi Shen *Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China.ORCID http://orcid.org/0009-0002-2387-8484 Meng Shan *Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China. 20185232056@stu.suda.edu.cn.ORCID http://orcid.org/0000-0002-1606-555X Mengqian Chu *Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China.
Yiming CaiJiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China.
Jingwen RuiJiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China.
Suning ChenJiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China.
Depei WuJiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China.ORCID http://orcid.org/0000-0002-6312-3863 Yang XuJiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China. xuyang1020@126.com.ORCID http://orcid.org/0000-0003-4643-2098 Funding
National Natural Science Foundation of China (National Science Foundation of China) 82070187National Natural Science Foundation of China (National Science Foundation of China) 82370213
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Identifiers
PMID39934109
PMCPMC11814316
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390